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HepatotoxicityAbstract Background: The prevalence of hepatitis C virus (HCV) infection among patients with
tuberculosis (TB) has not been extensively investigated, and very limited data on rates of HCV
co-infection among patients with TB exists. Hepatotoxicity is the major adverse effect of three of
the ﬁrst line anti-TB agents: isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA). Chronic
liver disease raises a risk of hepatotoxicity during anti-tuberculosis treatment, up to three to ﬁve
times more than TB patients who do not have viral infection.
Aim: To assess the prevalence of HCV infection in patients with tuberculosis and its impact in
the incidence of anti-tuberculosis drug induced hepatotoxicity (DIH).
Subjects and methods: The prevalence of HCV in patients with newly diagnosed pulmonary or
extrapulmonary tuberculosis was estimated using polymerase chain reaction (PCR). Then patients
were classiﬁed into 2 groups: group I (patients with HCV-TB coinfections) and group II (HCV-
seronegative tuberculous patients). Baseline and monthly measuring liver transaminases was done
before and following the start of 1st line anti-tuberculosis therapy.
Results: The prevalence of HCV in patients with TB was 17.02%. Regarding DIH, in group I; 6
(40%) cases showed transient transaminase elevations and 6 (40%) cases developed DIH. In group
II; 11 (20.75%) cases developed transient transaminase elevations and only 2 (3.78%) cases devel-
oped DIH, and there was a highly signiﬁcant difference (<0.01) between both groups. Regarding
the severity of DIH, in group I; 4 cases were mild, one case was moderate and one case was severe.
While in group II, no cases was with severe DIH. The risk factors for developing DIH during
anti-tuberculosis therapy were; age P40, high baselines transaminases, ALP and total bilirubin,d.
92 M.A. Agha et al.and low BMI. Most cases of DIH occurred during the 1st 4 weeks of starting anti-tuberculosis
therapy (66.7% and 50% in group I and group II, respectively).
Conclusions: Tuberculosis and hepatitis C virus co-infection is common, and elevation of liver
functions during anti-tuberculosis therapy is not uncommon. HCV-positive patients with tubercu-
losis should be closely monitored during treatment especially if they had elevated baseline liver
functions, old age and with low BMI. Monitoring should include the whole period of treatment,
especially the 1st 2 months.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Tuberculosis remains a leading health problem in both develop-
ing anddeveloped countries [1]. TheWorldHealthOrganization
(WHO) estimates that there were 8.6 million new cases of TB
globally in 2012 and 1.3 million deaths [2]. Hepatitis C virus is
a well-known agent of liver diseases, including chronic hepatitis,
cirrhosis and hepatocellular carcinoma [3,4]. Hepatitis C virus
has a positive sense single-stranded RNA genome that presents
a high degree of genetic heterogeneity.HCV strains are classiﬁed
into six genotypes (1–6), each comprising multiple subtypes
(designated a, b, c, etc.) [5,6]. A seventh genotype (subtype 7a)
was recently discovered [7].Hepatitis C virus infection is a global
public health problem.Hepatitis C virus affects over 200million
people, with an estimated HCV prevalence of 2.2% globally. It
has been estimated that HCV accounts for 27% of cirrhosis and
25% of hepatocellular carcinoma cases worldwide. Global and
region-speciﬁc estimates of HCV prevalence vary greatly, but
the highest prevalence (15–20%) has been reported from Egypt
[8–9]. HCV is characterized by a high degree of genetic
heterogeneity [10]. Globally, the prevalence of HCV infection
among patients with TB has not been extensively investigated,
and very limited data on rates of HCV co-infection among
patients with TB exists [11]. Hepatotoxicity is the major adverse
effect of three of the ﬁrst line anti-TB agents: isoniazid, rifampin,
and pyrazinamide [12]. Chronic liver disease raises a risk of hep-
atotoxicity during anti-tuberculosis treatment, up to three to
ﬁve times more than TB patients who do not have viral infection
[13]. Similarly, fourteen fold increase in the risk of anti-TB hep-
atotoxicity has been reported in HIV and HCV co-infected
patients [14]. Patients with increased susceptibility to the hepa-
totoxic effects of ﬁrst-line treatment regimens represent special
populations and need to be identiﬁed prior to therapy initiation
and monitored more carefully. Although three of the ﬁrst-line
drugs, rifampin, pyrazinamide, and isoniazid are known to be
hepatotoxic [15–20], the patient characteristics that confer
greater risk of treatment-associated liver injury are poorly
understood. Older age, concurrent or chronic alcohol use,
hepatitis C, hepatitis B, and HIV virus infection have been
found to increase the risk ofDIH [21–23].Until deﬁnitive studies
are conducted, caution suggests that patient populations should
be screened for the above-mentioned characteristics and
monitored carefully following the initiation of therapy [24].
Aim of the work
The aim of this work was to assess the prevalence of HCV
infection in patients with TB and its impact on the incidence
of anti-tuberculosis therapy induced hepatotoxicity.Subjects and methods
This study included 94 patients with newly diagnosed pulmon-
ary or extrapulmonary TB admitted to Chest Department,
Menouﬁya University Hospitals, from February 2013 to
February 2014. At the baseline visit 10 ml of blood was drawn
to test for HCV antibodies, HBV antibodies and liver enzymes;
ALT, AST, alkaline phosphatase (ALP), total bilirubin and
albumin (ALB). In cases withHCVantibodies seropositive, they
were sent for doing PCR. The prevalence of HCV in patients
with TB was estimated. The following patients were excluded:
patients with abnormal baseline aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) levelsP120 IU/L; with
underlying malignancy; patients with chronic liver disease;
patients started anti-tuberculosis therapy; and patients who
were unavailable for 6 months follow up. Included patients
started anti-tuberculosis treatment that included an intensive
phase of four drugs isoniazid, rifampicin, pyrazinamide, and
ethambutol for two months, followed by a continuation phase
of RIF and INH for four months using WHO dosing recom-
mendations [25]. Monthly follow-up visit included measuring
ALT, and AST levels were done. Patients were encouraged to
return at any time if new symptoms arose during therapy.
DIH was deﬁned when liver transaminase levels were
>120 IU/L. If the AST/ALT levels were <200 IU/L, the DIH
was deﬁned asmild. AST/ALT levels of 200–500 IU/L indicated
moderate hepatotoxicity, andAST/ALT levelsP500 IU/Lwere
considered to indicate severe hepatotoxicity [26].
Transient transaminase elevation was diagnosed if AST/ALT
levels were increased but were still less than three times the upper
normal limit (120 IU/L) and resolved spontaneously despite con-
tinued anti-TBmedications [27]. Patients exhibiting mild increases
in liver transaminase levels, but without clinical symptoms, were
carefully observed with no changes in treatment. In the case of a
patient who exhibited symptoms suggesting DIH, who also
showed markedly increased liver transaminase levels (P3 times
their normal values), all hepatotoxic drugs were stopped. These
drugs were then replaced with non-hepatotoxic drugs, such as
ethambutol, quinolones, and aminoglycosides. After liver trans-
aminase normalization, the hepatotoxic drugs were reintroduced.
RIF therapy was reintroduced ﬁrst, at progressively increasing
dosages, and then INH therapy was restarted. The targeted
treatment regimen usually included INH, RIF, and ethambutol,
without pyrazinamide. If symptoms recurred or liver transaminase
levels increased during the reintroduction of therapy with
hepatotoxic drugs, the offending drug was withdrawn, and
non-hepatotoxic drug therapy was maintained [28].
Anti-HCV antibody assay: the test was done using the
Architect anti HCV kit (Abbott, Germany). Principle: The test
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luminescent assay. In the ﬁrst step; sample, recombinant HCV
antigen coated paramagnetic microparticles and assay diluent
were combined. Anti-HCV antibodies (if present) bound to
the antigen coating the microparticles. Second step included a
washing step followed by addition of anti-human acridinium-
labeled conjugate. After another washing step, pre-trigger and
trigger solutions were added. The resulting chemi-luminescent
reaction was measured by the Architect i* system optics as rel-
ative light units which was proportional to the amount of
anti-HCV Ab in the sample. PCR: HCV RNA detection: Real
time quantitative reverse transcriptase PCR: RNA was
extracted using Promega RNA extraction kit (Abbott).
Then real time quantitation of HCV RNA PCR was done
using Abbott m 2000rt instrument system, Abbott Molocula
Inc., Des. Plaines 1L60018, Singapore.
Statistical methodology [29]
Data collected were tabulated and analyzed by SPSS (statisti-
cal package for the social science software) statistical package
version 11 on an IBM compatible computer. Two types of
statistics were done:
1. Descriptive statistics: Quantitative data are expressed to
measure the central tendency of data and diversion around
the mean, mean (x) and standard deviation (SD).
Qualitative data were expressed in number and percentage.
2. Analytic statistics: Students T test was used for the compar-
ison of two quantitative variables, Mann Whitney test was
used to compare between two groups of quantitative data
not normally distributed; and chi-square (v2) tests were
used to compare categorical outcomes.
 P value > 0.05 was considered statistically non-
signiﬁcant.
 P value 6 0.05 was considered statistically signiﬁcant.
 P value 6 0.001 was considered statistically highly
signiﬁcant.
Results
This study included 94 patients with newly diagnosed tubercu-
losis (70 cases were pulmonary, 20 cases were pleural, and 4
cases of TB lymphadenopathy). 18 cases were HCV antibodiesTable 1 Baseline characteristics of the studied groups.
Group I (n= 15) Group




Baseline ALT 45.6 ± 13 31 ± 1
Baseline AST 49.12 ± 14.7 33 ± 1
Baseline ALB 3.2 ± 1.7 3.4 ±
Baseline ALP 105 ± 30.34 89.34 ±
Baseline total bilirubin 1 ± 0.15 0.9 ±
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP,
highly signiﬁcant difference; NS, non-signiﬁcant difference.seropositive but using PCR, HCV was conﬁrmed in 16 cases (2
false positive cases) and the prevalence of HCV in patients
with tuberculosis was 17.02%. The patients were classiﬁed into
2 groups: group I (patients with HCV-TB co-infection) and
group II (TB patients without HCV infection). 3 cases (2 cases
were HCV negative with PCR and one case was HCV and
HBV co-infection) were excluded from group I before starting
anti-tuberculosis drugs, while 25 cases (5 cases of HBV sero-
positive, 3 patients with malignancy, 3 cases with history of
chronic liver disease, 8 cases could not be followed up for
6 months, and 6 cases started anti-TB drugs), were excluded
from group II. Table 1 shows that there was no signiﬁcant dif-
ference between the 2 studied groups regarding gender, but
there was signiﬁcant difference regarding age (p value <0.05)
as patients of group I were older than those of group II.
Regarding baseline liver function tests, Table 1 shows that
group I had a higher baseline levels of ALT, AST, bilirubin
and ALP and there was a highly signiﬁcant difference
(<0.01) between both groups regarding ALT, AST and
ALP, and a signiﬁcant difference regarding total bilirubin
(<0.05) while there was a non-signiﬁcant difference regarding
albumin although it was higher in group II than group I.
Regarding DIH, Table 2 shows that in group I; 6 (40%) cases
showed transient transaminase elevations and 6 (40%) cases
developed DIH. In group II; 11 (20.75%) cases developed
transient transaminase elevations and only 2 (3.78%) cases
developed DIH, and there was a highly signiﬁcant difference
(<0.01) between both groups. Regarding the severity of
DIH, Table 3 shows that in group I; 4 cases were mild, one
case was moderate and one case was severe. While in group
II; one case was mild and one case was moderate DIH with
no cases of severe DIH. Table 4 shows that the risk factors
for developing DIH during anti-tuberculosis therapy were;
age more than 40, high baselines transaminases, ALP and total
bilirubin, and low BMI. While Table 5 shows that most cases
of DIH occurred during the 1st 4 weeks of starting anti-tuber-
culosis therapy (66.7% and 50% in group I and group II,
respectively).Discussion
This study included 94 patients with newly diagnosed TB (70
cases were pulmonary, 20 cases were pleural, and 4 cases of
TB lymphadenopathy) admitted to the Chest Department,
Menouﬁya University Hospitals, from February 2013 to
March 2014. Regarding the prevalence of HCV in patientsII (n= 53) Student test P-Value
13.3 2.01 0.048 < 0.05 S
Chi square 0.273 NS
1.20
1.9 4.10 <0.001 HS
0.3 4.83 <0.001 HS
1.49 0.44 0.658
19 2.43 0.017 < 0.05 S
0.11 2.85 0.0058 < 0.01 HS
alkaline phosphatase; ALB, albumin; S, signiﬁcant difference; HS,
Table 2 Comparisons between both groups regarding DIH.
DIH Group I (n= 15) Group II (n= 53) Chi square P-Value
No 3 (20%) 40 (75.47%) 20.46 <0.001 HS
Transient 6 (40%) 11 (20.75%)
DIH 6 (40%) 2 (3.78%)
HS, highly signiﬁcant difference; DIH, drug induced hepatotoxicity.
Table 3 Degree of severity of DIH.
DIH Group I Group II Chi square P-Value




NS, non-signiﬁcant difference; DIH, drug induced hepatotoxicity.
Table 5 Timing of DIH.
Timing Group I Group II
64 wk 4 1
4–8 wk 1 1
8–12 wk 1 0
12–16 wk 0 0
16–20 wk 0 0
20–24 wk 0 0
DIH, drug induced hepatotoxicity; Wk, weak.
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PCR, HCV was conﬁrmed in 16 cases (prevalence was
17.02%). In Egypt nearly 10% had chronic HCV infection;
overall, an estimated 6 million Egyptians had chronic HCV
infection in 2008. Prevalence of chronic HCV infection in
Egypt is 10–12% [30]. Prevalence rate of HCV among TB
patients varies internationally. Many Results of HCV preva-
lence (7.5%) was documented by Reis et al. [31], whereas in
Thailand, a study revealed very high prevalence for HCV
(31%) [32]. Another study conducted in Georgia, Richards
et al. [12] found that 22% were HCV seropositive, Kuniholm
et al. [33] revealed 12% HCV positives, Wang et al. [34]
showed HCV 6.7%, Khalil et al. [35] reported HCV co-infec-
tions in TB were 28 (27.45%). In the study of Akhtar et al.
[36] prevalence of HCV was 9.1% using ELISA technique in
TB patient. In the study of Badawy et al. [37] who studied
Hundred thirty-ﬁve tuberculosis patients with tuberculosis
either pulmonary or extra pulmonary, they found that HCV
infection was diagnosed in 21/135 (prevalence was 6.4%). This
variation among results may be due to the use of conventionalTable 4 Risk factors for DIH.
Factor DIH (n= 8) No-HIH




Baseline ALT 45.33 ± 15.81 30 ± 8.
Baseline AST 49.25 ± 16.22 33 ± 9.
Baseline albumin 3.10 ± 1.52 3.4 ± 0








ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP:
highly signiﬁcant difference; NS: non-signiﬁcant difference; DIH: drug inand different techniques including ELISA, PCR, and recombi-
nant immunoblot assay (RIBA). The patients were classiﬁed
into 2 groups: group I (patients with HCV-TB co-infection)
and group II (HCV-negative tuberculous patients). There
was no signiﬁcant difference between the 2 studied groups
regarding gender, but there was signiﬁcant difference regarding
age (p value <0.05) as patients of group I were older than
those of group II. Regarding baseline liver function tests,
group I had a higher baseline levels of ALT, AST, bilirubin
and ALP and there was highly signiﬁcant difference (<0.01)
between both groups regarding ALT, AST and ALP, and a
signiﬁcant difference regarding total bilirubin (<0.05) while
there was non-signiﬁcant difference regarding albumin
although its levels were lower in group I than group II.
Regarding DIH, in group I; 6 (40%) cases showed transient
transaminase elevations and 6 (40%) cases developed DIH.
In group II; 11 (20.75%) cases developed transient transami-












alkaline phosphatase; ALB: albumin; S: signiﬁcant difference; HS:
duced hepatotoxicity.
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both groups. Regarding the severity of DIH, in group I; 4 cases
were mild, one case was moderate and one case was severe.
While in group II; one case was mild and one case was
moderate DIH with no cases of severe DIH. The present study
is an agreement with that of Ungo et al. [13] who investigated
the association of HCV infection and the development of DIH
during anti-TB treatment. DIH, which was deﬁned as a liver
transaminase level P120 IU/L, occurred more frequently in
HCV-seropositive and HIV-seronegative patients (7 of 29
patients, 24%) than in HCV-seronegative and HIV-seronega-
tive patients (3 of 55, 5%). Also the study of Kwon [26]
included >50 HCV-seropositive patients, and revealed that
the elevation of liver enzyme levels during standard therapy
for TB was more common in HCV-seropositive patients
(41%) than in the control subjects (20%) and DIH occurred
more frequently in HCV-seropositive patients (13%) than in
control subjects (4%). Sadaphal et al. [22] evaluated the risk
of DIH in a cohort of 146 injection drug users, 95% of whom
were HCV seropositive, who were treated with isoniazid for
latent TB infection. In their study, an increase in liver transam-
inase values to more than three times the upper limit of normal
occurred in 22% of patients. Fernandez-Villar et al. [38] also
studied the risk of DIH among 415 drug users, 52% of whom
were HCV seropositive, with isoniazid treatment for latent TB
infection. The presence of HCV antibodies was associated with
DIH (16 of 214 HCV-seropositive patients [7.5%] vs 4 of 201
control subjects [2%]) [38]. In study of Lomtadze et al. [39],
18.8% of subjects with a normal baseline ALT level developed
DIH during the treatment, indicating an important increase
from baseline ALT level during the six months of anti-TB ther-
apy, while among patients with HCV co-infection, 43.8%
developed hepatotoxicity, nearly double the proportion of
chronic hepatitis patients with incident hepatotoxicity reported
by Park et al. in Korea [40]. In the study of Sun et al. [41],
abnormal liver function tests at baseline and liver cirrhosis
were identiﬁed as independent risk factors for the development
of hepatitis during anti-tuberculosis treatment. Teleman et al.
[42] also showed that patients with abnormal baseline transam-
inase were at risk for the development of hepatitis during treat-
ment, and Cho et al. [43] demonstrated that patients with liver
cirrhosis have an insigniﬁcantly higher incidence of hepatitis
than those without liver disease (27% vs. 10%, p= 0.079).
Prior studies have demonstrated that transient elevation of
AST/ALT (1–3 times higher than ULN) was observed in
26% of HBV carriers and 28% of HCV carriers [44]. Shakya
et al. [45] reported that 38% and 40% of patients undergoing
anti-tuberculosis treatment had ALT and AST levels two times
higher than the pretreatment level. In the study of Sun et al.
[41], they found that 50% and 40% of the patients without
hepatitis had elevated AST and ALT level higher than ULN,
and 19% and 15% had elevated AST and ALT levels > 2
times ULN. The risk factors for developing DIH during
anti-tuberculosis therapy were; age more than 40, high base-
lines transaminases, ALP and total bilirubin, and low BMI.
Makhlouf et al. [46] who studied 26 TB patients of pulmonary
and extrapulmonary TB associated with liver cirrhosis or viral
hepatitis in addition to 46 TB patients without liver disease as
controls, by univariate analysis, liver diseased patients with
anti-TB-DIH had lower body mass index (P< 0.049) and
lower serum albumin (P= 0.008). Using multivariateregression analysis proved that lower serum albumin was
independent predictors of anti-TB-DIH (P< 0.018) in liver
diseased patients while the presence of other co-morbid dis-
eases was the only risk factor in patients without liver disease
(P< 0.024). Regarding the timing of DIH; in the present work
most cases of DIH occurred during the 1st 4 weeks of starting
anti-tuberculosis therapy (66.7% and 50% in group I and
group II, respectively) which is in agreement with the study
of Makhlouf et al. [46], who found that Anti-TB-DIH devel-
oped within 15–60 days from the onset of therapy.
Conclusion
Tuberculosis and hepatitis C virus co-infection is common,
and elevation of liver functions during anti-tuberculosis ther-
apy is not uncommon. Serologic screening of patients with
tuberculosis for HCV to identify patients in need of intensive
monitoring during anti-tuberculosis therapy may reduce the
risk of DIH. HCV seropositive patients with tuberculosis
should be closely monitored during treatment especially if they
had elevated baseline liver functions, old age and with low
BMI. Monitoring should include the whole period of treat-
ment, especially the 1st 2 months.
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